Prospective Pilot Study of Plasma Cell-Targeted Therapy With Bortezomib in Refractory IgA Nephropathy.

ABSTRACT:

Introduction

IgA nephropathy (IgAN) is a leading cause of kidney failure, characterized by galactose-deficient IgA1 (Gd-IgA1) deposition and immune complex formation. Aberrant trafficking of IgA+ plasma cells and autoantibody production (IgG or IgA) contribute to disease pathogenesis. Proteasome inhibitors such as bortezomib may modulate B or plasma cell activity and reduce pathogenic antibody production.

Methods

This open-label, prospective, uncontrolled trial evaluated bortezomib in adults with biopsy-confirmed IgAN, proteinuria > 1.5 g/d, and estimated glomerular filtration rate (eGFR) ≥ 30 ml/min per 1.73 m² despite optimized care. Patients received 4 to 8 doses of i.v. bortezomib at 1.1 to 1.3 mg/m² per dose. The primary end point was achieving 24-

SUBMITTER: Lin L 

PROVIDER: S-EPMC12446934 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature